Skip to main content
Have a personal or library account? Click to login
Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms– Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience Cover

Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms– Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience

PRILOZI
Volume 44 (2023): Issue 3 (December 2023)
By: Marija Popova-Labachevska,  Milche Cvetanoski,  Nevenka Ridova,  Sanja Trajkova,  Simona Stojanovska-Jakimovska,  Tara Mojsovska,  Zlate Stojanoski,  Aleksandra Pivkova-Veljanovska and  Irina Panovska-Stavridis  
Open Access
|Dec 2023
Articles in this issue
DOI: https://doi.org/10.2478/prilozi-2023-0047 | Journal eISSN: 1857-8985 | Journal ISSN: 1857-9345
Journal RSS Feed
Language: English
Page range: 57 - 62
Published on: Dec 18, 2023
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year
Keywords:
Essential Thrombocythemia,
Polycythemia Vera,
Primary Myelofibrosis,
myeloproliferative neoplasms,
ropeginterferon alfa-2b
Related subjects:
Medicine,
Basic medical science,
History and ethics of medicine,
Clinical medicine,
Clinical medicine, other,
Social sciences,
Education,
Education, other

© 2023 Marija Popova-Labachevska, Milche Cvetanoski, Nevenka Ridova, Sanja Trajkova, Simona Stojanovska-Jakimovska, Tara Mojsovska, Zlate Stojanoski, Aleksandra Pivkova-Veljanovska, Irina Panovska-Stavridis, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 44 (2023): Issue 3 (December 2023)
Previous article
Next article